Skip to content

Immunovant, Inc. IMVT Ratios & Valuation

FY'26FY'25FY'24FY'23
Returns
Return on equity-64.8%-2.4pp-62.5%-9.5pp-52.9%-2.2pp-50.7%-14.3pp
Return on assets-58.3%-1.0pp-57.4%-9.0pp-48.4%-2.6pp-45.8%-12.0pp
Liquidity
Current ratio9.1×-2.1×11.2×-2.5×13.7×+4.4×9.3×-2.2×
Quick ratio9.1×-2.1×11.2×-2.5×13.7×+4.4×9.3×-2.2×
Cash ratio8.6×-1.7×10.4×-2.7×13.1×+4.4×8.7×-2.4×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Interest coverage-19×-3.3×-15.7×-6.3×-9.4×+17.5×-26.8×
Per Share
Book value per share$4.67+0.1%$4.67+4.3%$4.47+51.9%$2.95-31.2%
Valuation
Market capitalization$5.06B+74.2%$2.9B-37.8%$4.67B+131%$2.02B+215%
Enterprise value$4.15B+89.7%$2.19B-45.7%$4.03B+145%$1.65B+994%
Price / book5.9×+1.8×4.1×-3.5×7.6×+2.0×5.6×+4.2×
Free cash flow yield-8.1%+4.9pp-13%-8.4pp-4.6%+4.7pp-9.3%+7.3pp
Earnings yield-10%+4.3pp-14.3%-8.7pp-5.6%+4.9pp-10.4%+14.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immunovant, Inc.'s ratios come from?
Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.